Symbols

MTVA

MetaVia·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MTVA

Metavia Inc.

A biotechnology company dedicated to developing drugs for the treatment of cardiovascular metabolic diseases

Industry

Pharmaceutical

Established Date

11/10/2008

Listing Date

08/05/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.neurobopharma.com

Security Type

Common stock

Office address

545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138

Business

Introduction

MetaVia Inc., was incorporated in Michigan on November 10, 2008 under the name Michigan Life Therapeutics, LLC (MLT). NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on the development and commercialization of new drugs for the treatment of cardiometabolic diseases. NeuroBo has two main programs, focusing on the treatment of non-alcoholic steatohepatitis (NASH), obesity and type 2 diabetes (T2D).

Company Financials

EPS

MTVA has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -0.25, beating expectations. The chart below visualizes how MTVA has performed over recent quarters, highlighting trends in earnings surprises.